Skip to content
Catalyst

sucraloseWhat was measured

Measured, with no finding

168 endpoints

Show what was measuredHide what was measured
  • cariogenic potential of sucralose-based sweeteners with bulking ingredients versus sugar

    decreases

    the data suggest that both the currently marketed sucralose granular and packet products are less cariogenic than sugar

    PMID 11887514 · one of two readings recorded this

  • cariogenic potential of sucralose

    no effect

    The sum of these studies demonstrates that sucralose is non-cariogenic.

    PMID 11887514 · one of two readings recorded this

  • blood glucose

    increases, p = 0.05

    Blood glucose increased only in response to sucrose (P<0.05)

    PMID 19221011 · one of two readings recorded this

  • gastric emptying t50

    Gastric emptying of sucrose was slower than that of saline (t50: 87.4+/-4.1 min vs. 74.7+/-3.2 min, P<0.005)

    PMID 19221011 · one of two readings recorded this

  • gastric emptying t50

    no effect

    there were no differences in t50 between sucralose 0.4 mM (73.7+/-3.1 min) or 4 mM (76.7+/-3.1 min) and saline

    PMID 19221011 · one of two readings recorded this

  • gastric emptying t50

    no effect

    there were no differences in t50 between sucralose 0.4 mM (73.7+/-3.1 min) or 4 mM (76.7+/-3.1 min) and saline

    PMID 19221011 · one of two readings recorded this

  • gastric emptying t50

    decreases, p = 0.005

    Gastric emptying of sucrose was slower than that of saline (t50: 87.4+/-4.1 min vs. 74.7+/-3.2 min, P<0.005)

    PMID 19221011 · one of two readings recorded this

  • plasma GLP-1, GIP and insulin after intragastric infusion

    no effect, GLP-1, GIP and insulin increased after sucrose but not after either sucralose load

    Not recorded as a finding: plasma-glp-1 is defined for a mixed-nutrient drink or intraduodenal infusion, not an intragastric non-nutrient load; GIP and insulin have no node on this path; abstract-only and the sentence lumps sucralose with saline

    GLP-1, GIP, and insulin also increased after sucrose (P=0.0001) but not after either load of sucralose or saline.

    PMID 19221011 · one of two readings recorded this

  • plasma GLP-1, GIP and insulin

    no effect

    GLP-1, GIP, and insulin also increased after sucrose (P=0.0001) but not after either load of sucralose or saline

    PMID 19221011 · one of two readings recorded this

  • plasma GLP-1, GIP and insulin

    increases, p = 0.0001

    GLP-1, GIP, and insulin also increased after sucrose (P=0.0001) but not after either load of sucralose or saline

    PMID 19221011 · one of two readings recorded this

  • average plasma GIP concentration

    no effect, p = 0.08

    Although average plasma GIP concentrations tended to be higher after sucralose than after water ingestion (20 ± 8 vs. 18 ± 7 pmol/L), the difference was not statistically significant (P = 0.08)

    PMID 23633524 · one of two readings recorded this

  • dynamic insulin secretion rate curves

    no effect

    the dynamic ISR curves were the same after sucralose and water ingestion

    PMID 23633524 · one of two readings recorded this

  • incremental AUC of insulin after a 75 g oral glucose load, immunoenzymatic assay

    increases, incremental AUC of insulin 20 +/- 8% greater after sucralose than water

    Not recorded as a finding: no outcome node for plasma insulin response to an oral glucose load (stimulated-postprandial-insulin requires an amino-acid preload)

    However, the incremental AUC of insulin was 20 ± 8% greater after sucralose than after water ingestion (P < 0.03) (Table 1).

    PMID 23633524 · one of two readings recorded this

  • incremental AUC of plasma glucose after 75 g oral glucose load over 5 h

    no effect, no significant differences in incremental AUC of glucose

    Not recorded as a finding: postprandial-glucose-auc defines a 60 to 120 minute window; the paper samples to 300 min

    No significant differences in the incremental AUC of glucose or C-peptide were detected in response to the glucose load after sucralose and water ingestion.

    PMID 23633524 · one of two readings recorded this

  • incremental AUC of plasma glucose and C-peptide

    no effect

    No significant differences in the incremental AUC of glucose or C-peptide were detected in response to the glucose load after sucralose and water ingestion

    PMID 23633524 · one of two readings recorded this

  • incremental AUC of plasma glucose over a 5-h 75 g OGTT, YSI analyzer

    no effect, no significant difference in incremental glucose AUC after sucralose versus water

    Not recorded as a finding: node postprandial-glucose-auc specifies a 60 to 120 minute window; this paper's AUC spans 5 h

    No significant differences in the incremental AUC of glucose or C-peptide were detected in response to the glucose load after sucralose and water ingestion.

    PMID 23633524 · one of two readings recorded this

  • incremental AUC of plasma insulin after glucose load

    increases, p = 0.03

    the incremental AUC of insulin was 20 ± 8% greater after sucralose than after water ingestion (P < 0.03)

    PMID 23633524 · one of two readings recorded this

  • incremental insulin AUC after an oral glucose load, two-site immunoenzymatic assay

    increases, incremental AUC of insulin 20 +/- 8% greater after sucralose than water, p = 0.03

    Not recorded as a finding: no insulin node for an oral glucose load; stimulated-postprandial-insulin requires an amino-acid preload

    However, the incremental AUC of insulin was 20 ± 8% greater after sucralose than after water ingestion (P < 0.03) (Table 1).

    PMID 23633524 · one of two readings recorded this

  • insulin clearance rate after glucose load

    decreases, p = 0.05

    Sucralose ingestion decreased the insulin clearance rate after ingesting the glucose load by 7 ± 4% (P < 0.05)

    PMID 23633524 · one of two readings recorded this

  • insulin sensitivity index SI from a minimal model of glucose and insulin

    decreases, median SI 23 +/- 20% lower after sucralose than water

    Not recorded as a finding: no outcome node for minimal-model insulin sensitivity

    The median SI value was 23 ± 20% lower after sucralose than after water ingestion (P < 0.01) (Table 1).

    PMID 23633524 · one of two readings recorded this

  • insulin sensitivity index SI from minimal model of glucose and insulin

    decreases, median SI 23 +/- 20% lower after sucralose than water, p = 0.01

    Not recorded as a finding: no outcome node for minimal-model insulin sensitivity

    The median SI value was 23 ± 20% lower after sucralose than after water ingestion (P < 0.01) (Table 1).

    PMID 23633524 · one of two readings recorded this

  • insulin sensitivity index SI (median)

    decreases, p = 0.01

    The median SI value was 23 ± 20% lower after sucralose than after water ingestion (P < 0.01)

    PMID 23633524 · one of two readings recorded this

  • peak plasma glucose concentration

    increases

    Mean peak plasma glucose concentration was higher and the subsequent nadir was lower after sucralose than after water ingestion

    PMID 23633524 · one of two readings recorded this

  • peak plasma insulin and C-peptide concentrations

    increases

    Peak plasma insulin and C-peptide concentrations were also higher after sucralose than after water ingestion

    PMID 23633524 · one of two readings recorded this

  • plasma active GLP-1 and GIP incremental AUC, immunoassay, after 75 g glucose

    no effect, not different after sucralose or water ingestion

    Not recorded as a finding: plasma-glp-1 and plasma-gip nodes specify a fixed mixed-nutrient drink or intraduodenal infusion, not a 75 g glucose load; the sentence reports two analytes together

    Plasma active GLP-1 concentration, incremental GLP-1 AUC, and incremental GIP AUC after the glucose load were not different after sucralose or water ingestion (and Table 1).

    PMID 23633524 · one of two readings recorded this

  • plasma active GLP-1 concentration and incremental GLP-1 AUC after oral glucose load, Meso Scale Discovery immunoassay

    no effect, not different after sucralose or water

    Not recorded as a finding: plasma-glp-1 is defined after a mixed-nutrient drink or intraduodenal infusion, not an oral glucose load; sentence also lumps GIP AUC

    Plasma active GLP-1 concentration, incremental GLP-1 AUC, and incremental GIP AUC after the glucose load were not different after sucralose or water ingestion (and Table 1).

    PMID 23633524 · one of two readings recorded this

  • plasma active GLP-1 concentration, GLP-1 incremental AUC and GIP incremental AUC

    no effect

    Plasma active GLP-1 concentration, incremental GLP-1 AUC, and incremental GIP AUC after the glucose load were not different after sucralose or water ingestion

    PMID 23633524 · one of two readings recorded this

  • plasma glucagon concentration and decremental glucagon AUC

    no effect

    Plasma glucagon concentration and the decremental glucagon AUC after the glucose load were similar after sucralose and water ingestion

    PMID 23633524 · one of two readings recorded this

  • static insulin secretion rate between 60 and 105 min

    increases, p = 0.005

    an average increase of ∼22 ± 4% in the static ISR between 60 and 105 min (P < 0.005)

    PMID 23633524 · one of two readings recorded this

  • total insulin secretion rate AUC and beta-cell sensitivity to glucose (Φtotal, Φdynamic, Φstatic)

    no effect

    Total ISR AUCs in response to the oral glucose load and the sensitivity of insulin secretion to plasma glucose (Φtotal, Φdynamic, and Φstatic) were not different between sucralose and water conditions (Table 1)

    PMID 23633524 · one of two readings recorded this

  • participants with detectable urinary sucralose after intervention

    unclear, n = 3

    sucralose was detected in 3 individuals randomly assigned to receive carbonated water (26-121 ng/mL; mean ± SD: 60.7 ± 52.4 ng/mL)

    PMID 28228424 · one of two readings recorded this

  • participants with detectable urinary sucralose after run-in

    unclear, n = 8

    sucralose was found in 8 individuals (2 of whom did not have detectable sucralose at baseline) and ranged from 25.0 to 1062.0 ng/mL (mean ± SD: 191.7 ± 354.2 ng/mL)

    PMID 28228424 · one of two readings recorded this

  • participants with detectable urinary sucralose at baseline

    unclear, n = 8

    At baseline, 8 participants had sucralose in their urine (29.9-239.0 ng/mL; mean ± SD: 111.4 ± 91.5 ng/mL)

    PMID 28228424 · one of two readings recorded this

  • active GLP-1 AUC

    increases, p = 0.001, n = 15

    AUC of active GLP-1 was significantly higher in the sucralose than placebo (23.16 ± 18.86 versus 18.5 ± 22.22 pmol/L ⋅ 120 min, P < 0.001)

    PMID 30005329 · one of two readings recorded this

  • acute insulin response (AIR) to glucose on IVGTT; Matsuda index; AUC of active GLP-1 after a 75 g OGTT, 200 mg sucralose pills versus placebo for 4 wk, crossover

    decreases, AIR 58.9 +/- 48.61 versus 69.94 +/- 73.81 uU/mL on sucralose versus placebo

    Not recorded as a finding: this platform holds no node for the endpoint

    AIR was lower after exposure to sucralose than placebo (58.9 ± 48.61 versus 69.94 ± 73.81 µU/mL, P < 0.001).

    PMID 30005329 · one of two readings recorded this

  • acute insulin response to glucose (AIR)

    decreases, p = 0.001, n = 15

    AIR was lower after exposure to sucralose than placebo (58.9 ± 48.61 versus 69.94 ± 73.81 µU/mL, P < 0.001)

    PMID 30005329 · one of two readings recorded this

  • whole-body insulin sensitivity by Matsuda index from a 75 g OGTT after 4 weeks of 200 mg sucralose pills versus placebo; acute insulin response on IVGTT; active GLP-1 AUC

    decreases, Matsuda index 4.69 ± 1.67 with sucralose versus 5.31 ± 2.56 with placebo

    Not recorded as a finding: this platform holds no node for the endpoint

    Whole-body insulin sensitivity (estimated using the Matsuda index) was lower in sucralose than placebo (4.69 ± 1.67 versus 5.31 ± 2.56, P < 0.005).

    PMID 30005329 · one of two readings recorded this

  • whole-body insulin sensitivity

    decreases, p = 0.005, n = 15

    Whole-body insulin sensitivity (estimated using the Matsuda index) was lower in sucralose than placebo (4.69 ± 1.67 versus 5.31 ± 2.56, P < 0.005)

    PMID 30005329 · one of two readings recorded this

  • acute insulin response to glucose

    increases, p = 0.04

    An increased acute insulin response to glucose from 577 mU · L-1· min (350-1040 mU · L-1· min) to 671 mU · L-1· min (376-1010 mU · L-1· min) (P = 0.04)

    PMID 30535090 · one of two readings recorded this

  • insulin sensitivity, acute insulin response to glucose, disposition index and glucose effectiveness by 3-h modified intravenous glucose tolerance test, 15% of Acceptable Daily Intake sucralose for 14 d versus no-intervention control

    decreases, median percentage change in insulin sensitivity -17.7% versus -2.8% in control, p = 0.04

    Not recorded as a finding: this platform holds no node for the endpoint

    Individuals assigned to sucralose consumption showed a significant decrease in insulin sensitivity with a median (IQR) percentage change of -17.7% (-29.3% to -1.0%) in comparison to -2.8% (-30.7% to 40.6%) in the control group (P= 0.04).

    PMID 30535090 · one of two readings recorded this

  • insulin sensitivity from a 3-h modified intravenous glucose tolerance test, sucralose 15% of ADI for 14 d versus a no-intervention control group

    decreases, median percentage change -17.7% (-29.3% to -1.0%) versus -2.8% (-30.7% to 40.6%) in controls, p = 0.04

    Not recorded as a finding: this platform holds no node for the endpoint

    Individuals assigned to sucralose consumption showed a significant decrease in insulin sensitivity with a median (IQR) percentage change of -17.7% (-29.3% to -1.0%) in comparison to -2.8% (-30.7% to 40.6%) in the control group (P= 0.04).

    PMID 30535090 · one of two readings recorded this

  • insulin sensitivity percentage change

    a median (IQR) percentage change of -17.7% (-29.3% to -1.0%) in comparison to -2.8% (-30.7% to 40.6%) in the control group (P= 0.04)

    PMID 30535090 · one of two readings recorded this

  • insulin sensitivity percentage change

    decreases, p = 0.04, n = 66

    a median (IQR) percentage change of -17.7% (-29.3% to -1.0%) in comparison to -2.8% (-30.7% to 40.6%) in the control group (P= 0.04)

    PMID 30535090 · one of two readings recorded this

  • blood glucose during OGTT

    no effect

    Blood glucose values showed no significant differences in subjects receiving placebo or sucralose all along the oral glucose tolerance test

    PMID 31183389 · one of two readings recorded this

  • CD11c expression on classical monocytes, -15 min versus 180 min

    decreases, p = 0.0008

    In classical monocytes, CD11c expression significantly diminished in the sucralose group at the beginning (-15 min) and at the end (180 min) of the OGTT (P = 0.0008)

    PMID 31183389 · one of two readings recorded this

  • CD11c expression on intermediate monocytes, -15 min versus 180 min

    decreases, p = 0.0004

    CD11c expression also exhibited a significant reduction in intermediate and nonclassical monocytes of subjects exposed to sucralose at the beginning (-15 min) and at the end (180 min) of the OGTT (P = 0.0004 and P = 0.0001, respectively)

    PMID 31183389 · one of two readings recorded this

  • CD11c expression on intermediate monocytes at 180 min

    decreases, p = 0.0012

    At 180 min, CD11c expression was significantly reduced in intermediate and nonclassical monocytes of subjects receiving sucralose as compared to placebo controls (P = 0.0012 and P = 0.0064, respectively)

    PMID 31183389 · one of two readings recorded this

  • CD11c expression on nonclassical monocytes, -15 min versus 180 min

    decreases, p = 0.0001

    CD11c expression also exhibited a significant reduction in intermediate and nonclassical monocytes of subjects exposed to sucralose at the beginning (-15 min) and at the end (180 min) of the OGTT (P = 0.0004 and P = 0.0001, respectively)

    PMID 31183389 · one of two readings recorded this

  • CD11c expression on nonclassical monocytes at 180 min

    decreases, p = 0.0064

    At 180 min, CD11c expression was significantly reduced in intermediate and nonclassical monocytes of subjects receiving sucralose as compared to placebo controls (P = 0.0012 and P = 0.0064, respectively)

    PMID 31183389 · one of two readings recorded this

  • CD206 expression on nonclassical monocytes at 180 min

    decreases, p = 0.0098

    At 180 min, CD206 expression was significantly reduced in nonclassical monocytes of volunteers that received sucralose as compared to placebo controls (P = 0.0098)

    PMID 31183389 · one of two readings recorded this

  • classical monocyte percentage at 180 min

    increases, p = 0.0028

    a significant 7% increase in the number of classical monocytes from subjects that received sucralose in comparison to controls receiving placebo (P = 0.0028)

    PMID 31183389 · one of two readings recorded this

  • correlation of blood glucose with monocyte subpopulations

    no effect

    Analysis of Pearson's correlation coefficients showed no significant associations of monocyte subpopulations with blood glucose (Table 2)

    PMID 31183389 · one of two readings recorded this

  • correlation of serum insulin with classical monocytes

    increases, p = 0.02

    serum insulin showed a positive relationship with classical monocytes (r = 0.41, P = 0.02)

    PMID 31183389 · one of two readings recorded this

  • correlation of serum insulin with nonclassical monocytes

    decreases, p = 0.01

    it also exhibited a strong inverse association with nonclassical monocytes (r = −0.42, P = 0.01)

    PMID 31183389 · one of two readings recorded this

  • intermediate monocyte percentage at 180 min

    no effect

    No significant differences were found in the percentage of intermediate monocytes in subjects that received placebo or sucralose

    PMID 31183389 · one of two readings recorded this

  • nonclassical monocyte percentage at 180 min

    decreases, p = 0.0001

    the nonclassical monocyte percentage exhibited a significant 63% reduction in subjects exposed to sucralose with respect to placebo controls (P < 0.0001)

    PMID 31183389 · one of two readings recorded this

  • serum insulin at timepoints of a 180-min OGTT, ELISA; blood glucose at OGTT timepoints; monocyte subpopulation percentages (classical, intermediate, nonclassical) by flow cytometry

    increases, 1.3-fold increase in serum insulin at 30 min versus placebo, p = 0.041

    Not recorded as a finding: this platform holds no node for the endpoint

    On the contrary, volunteers that received 48 mg sucralose prior glucose load showed a significant 1.3-fold increase in the serum levels of insulin at 30 min as compared to subjects drinking water as placebo (P = 0.041).

    PMID 31183389 · one of two readings recorded this

  • serum insulin during OGTT after a 48 mg sucralose sip versus water, ELISA; monocyte subpopulation percentages (CD14/CD16) by flow cytometry

    decreases, significant 63% reduction in nonclassical monocyte percentage versus placebo

    Not recorded as a finding: this platform holds no node for the endpoint

    On the other side, the nonclassical monocyte percentage exhibited a significant 63% reduction in subjects exposed to sucralose with respect to placebo controls (P < 0.0001).

    PMID 31183389 · one of two readings recorded this

  • serum insulin during OGTT at 180 min

    increases, p = 0.048

    At 180 min, subjects that received sucralose showed a significant 2-fold increase in the serum levels of insulin as compared to placebo controls (P = 0.048)

    PMID 31183389 · one of two readings recorded this

  • serum insulin during OGTT at 30 min

    increases, p = 0.041

    volunteers that received 48 mg sucralose prior glucose load showed a significant 1.3-fold increase in the serum levels of insulin at 30 min as compared to subjects drinking water as placebo (P = 0.041)

    PMID 31183389 · one of two readings recorded this

  • serum insulin during OGTT at 45 min

    increases, p = 0.046

    At 45 min, subjects receiving sucralose exhibited a significant 1.4-fold elevation in serum insulin with respect to placebo controls (P = 0.046)

    PMID 31183389 · one of two readings recorded this

  • Bacteroidetes and Firmicutes abundance

    modulates

    Independent of consuming sucralose or placebo, individuals with a higher insulinaemic response after the intervention had lower Bacteroidetes and higher Firmicutes abundances

    PMID 31258108 · one of two readings recorded this

  • body weight

    no effect

    During the study, body weight remained constant in both groups

    PMID 31258108 · one of two readings recorded this

  • glycaemic control and insulin resistance (HOMA-IR, Matsuda index)

    no effect

    Glycaemic control and insulin resistance were not affected during the 7-d period

    PMID 31258108 · one of two readings recorded this

  • gut microbiome at phylum level

    no effect

    At the phylum level, gut microbiome was not modified in any group

    PMID 31258108 · one of two readings recorded this

  • insulin resistance by HOMA-IR and Matsuda indexes after a 75 g oral glucose load; glycaemic and insulinaemic responses; gut microbiome by 16S rRNA sequencing; sucralose capsules 780 mg/d for 7 d versus placebo

    no effect, no alteration of glycaemic control, insulin resistance or gut microbiome

    Not recorded as a finding: a node exists but the paper states a different instrument or population

    In conclusion, consumption of high doses of sucralose for 7 d does not alter glycaemic control, insulin resistance, or gut microbiome in healthy individuals.

    PMID 31258108 · one of two readings recorded this

  • dynamic insulin secretion rate, treatment by weight group by time interaction

    modulates, p = 0.02

    Sucralose modified the ISR dynamic response to the glucose load only in the group with obesity (Treatment × Weight Group × Time: F(20,360) = 2.19; p < 0.02

    PMID 31877631 · one of two readings recorded this

  • endogenous glucose production suppression by glucose ingestion, obesity versus normal weight

    increases, p = 0.018

    Glucose ingestion suppressed EGP rapidly in both groups (p < 0.0001), but more so in participants with obesity (p = 0.018

    PMID 31877631 · one of two readings recorded this

  • insulin clearance rate after glucose load

    no effect, p = 0.08

    Ingested sucralose and sham-fed sucralose tended to increase the insulin clearance rate after ingesting the glucose load (p = 0.08; Table 2)

    PMID 31877631 · one of two readings recorded this

  • insulin clearance rate, obesity versus normal weight

    decreases, p = 0.09

    Participants with obesity were less insulin sensitive (p < 0.0005) and tended to have a slower rate of insulin clearance (p = 0.09) than normal-weight participants

    PMID 31877631 · one of two readings recorded this

  • insulin sensitivity SI, obesity versus normal weight

    decreases, p = 0.0005

    Participants with obesity were less insulin sensitive (p < 0.0005) and tended to have a slower rate of insulin clearance (p = 0.09) than normal-weight participants

    PMID 31877631 · one of two readings recorded this

  • insulin sensitivity SI, treatment by weight group interaction

    modulates, p = 0.02

    Sucralose differentially affected SI in participants with obesity and in normal-weight participants (Treatment × Weight- group: F(2,36) = 4.32; p < 0.02)

    PMID 31877631 · one of two readings recorded this

  • insulin sensitivity SI

    increases, p = 0.05

    Compared with water, sucralose increased SI by 52 ± 21% in normal-weight participants (p < 0.05)

    PMID 31877631 · one of two readings recorded this

  • insulin sensitivity SI

    no effect, p = 0.18

    Sham-fed sucralose also increased SI by 27 ± 13% in this group, but the difference from water treatment was not statistically significant (p = 0.18)

    PMID 31877631 · one of two readings recorded this

  • oral glucose rate of appearance during first 40 min of OGTT, weight group by time

    increases, p = 0.04

    Participants with obesity had a higher oral glucose rate of appearance during the first 40 min of the OGTT than normal-weight participants (Weight Group × Time: F(11,209) = 1.88, p = 0.04

    PMID 31877631 · one of two readings recorded this

  • peak plasma glucose, obesity versus normal weight

    decreases, p = 0.06

    the peak response in plasma glucose concentrations tended to be lower in participants with obesity than in normal-weight participants (p = 0.06

    PMID 31877631 · one of two readings recorded this

  • peak plasma sucralose concentration, obesity versus normal weight

    no effect, p = 0.31

    no significant differences between weight groups on peak sucralose concentrations (p = 0.31), time to peak (p = 0.11), or sucralose iAUC (p = 0.90

    PMID 31877631 · one of two readings recorded this

  • plasma C-peptide concentrations, treatment by weight group by time interaction

    no effect, p = 0.06

    the interaction between treatment, weight group, and time was not statistical significant (F(40,720) = 1.37; p = 0.06; Figure 1)

    PMID 31877631 · one of two readings recorded this

  • plasma GIP concentration 10 min post-OGTT, ingested versus sham-fed sucralose

    modulates, p = 0.001

    ingested sucralose affected plasma GIP concentrations 10 min post-OGTT in both weight groups, but in opposite ways (Treatment × Weight Group × Time: F(18,323) = 2.55; p < 0.001)

    PMID 31877631 · one of two readings recorded this

  • plasma glucose iAUC during OGTT

    increases, p = 0.03

    Sucralose ingested, but not sham-fed, increased the iAUC of plasma glucose by 30 ± 10% in both weight groups similarly (Treatment: F(2,36) = 3.99; p = 0.03

    PMID 31877631 · one of two readings recorded this

  • plasma insulin and C-peptide mean, peak and iAUC, obesity versus normal weight

    increases, p = 0.02

    Plasma insulin and C-peptide mean and peak concentrations, as well as iAUCs, were significantly higher in participants with obesity than in normal-weight participants (all p-values < 0.02

    PMID 31877631 · one of two readings recorded this

  • plasma insulin concentrations during first hour of OGTT

    decreases

    Compared with water treatment, sham-fed sucralose similarly reduced plasma insulin concentrations within the first hour of the OGTT in both weight groups

    PMID 31877631 · one of two readings recorded this

  • plasma insulin concentrations, treatment by weight group by time interaction

    modulates, p = 0.009

    whereas sucralose ingestion differentially affected insulin concentrations in the two weight groups (Treatment × Weight Group × Time: F(40,720) = 1.63; p = 0.009; Figure 1)

    PMID 31877631 · one of two readings recorded this

  • plasma sucralose concentration during last hour of OGTT, weight group by time

    increases, p = 0.004

    Participants with obesity had higher plasma sucralose concentrations than did normal-weight participants during the last hour of the OGTT (Weight Group x Time: F(9,162) = 2.98, p = 0.004

    PMID 31877631 · one of two readings recorded this

  • plasma sucralose iAUC, obesity versus normal weight

    no effect, p = 0.9

    no significant differences between weight groups on peak sucralose concentrations (p = 0.31), time to peak (p = 0.11), or sucralose iAUC (p = 0.90

    PMID 31877631 · one of two readings recorded this

  • time to peak plasma sucralose, obesity versus normal weight

    no effect, p = 0.11

    no significant differences between weight groups on peak sucralose concentrations (p = 0.31), time to peak (p = 0.11), or sucralose iAUC (p = 0.90

    PMID 31877631 · one of two readings recorded this

  • total and oral glucose rate of appearance

    no effect

    Sucralose, ingested or sham-fed, did not affect the total glucose rate of appearance or the oral glucose rate of appearance in either weight group

    PMID 31877631 · one of two readings recorded this

  • total and static insulin secretion rate and beta-cell glucose sensitivity

    no effect

    Treatment did not significantly affect the sensitivity of insulin secretion to plasma glucose or total or static ISR responses during the OGTT in either weight group

    PMID 31877631 · one of two readings recorded this

  • total, dynamic and static insulin secretion rate, obesity versus normal weight

    increases, p = 0.05

    Total, dynamic, and static ISR and the sensitivity of insulin secretion to plasma glucose in response to the OGTT were significantly higher in participants with obesity than in normal-weight participants across all treatments (all p < 0.05

    PMID 31877631 · one of two readings recorded this

  • adherence to intervention

    no effect, p = 0.16

    Adherence to intervention (%) | 94.14 ± 11.81 | 86.07 ± 19.12 | 87 ± 20.37 | 0.16

    PMID 32284053 · one of two readings recorded this

  • adherence to intervention

    no effect

    Adherence to intervention (%) | 94.14 ± 11.81 | 86.07 ± 19.12 | 87 ± 20.37 | 0.16

    PMID 32284053 · one of two readings recorded this

  • adherence to intervention

    no effect

    Adherence to intervention (%) | 94.14 ± 11.81 | 86.07 ± 19.12 | 87 ± 20.37 | 0.16

    PMID 32284053 · one of two readings recorded this

  • blood glucose during OGTT at 0 min, Wk10 vs Wk0

    increases, p = 0.04

    at 0 min (88.7 ± 4 mg/dL vs. 91.3 ± 6 mg/dL; p = 0.04)

    PMID 32284053 · one of two readings recorded this

  • blood glucose during OGTT at 120 min, Wk10 vs Wk0

    increases, p = 0.01

    at 120 min (95.2 ± 23.7 mg/dL vs 106.9 ± 19.5 mg/dL; p = 0.01)

    PMID 32284053 · one of two readings recorded this

  • blood glucose during OGTT at -15 min, Wk10 vs Wk0

    increases, p = 0.003

    at − 15 min (87.9 ± 4.6 mg/dL vs 91.4 ± 5.4 mg/dL; p = 0.003)

    PMID 32284053 · one of two readings recorded this

  • BMI, Wk10 vs Wk0

    no effect, p = 0.47

    48 mg sucralose | 24.2 ± 2.9 | 24.2 ± 3.1 | 0.47

    PMID 32284053 · one of two readings recorded this

  • BMI, Wk10 vs Wk0

    no effect, p = 0.56

    96 mg sucralose | 23.7 ± 3.3 | 23.6 ± 3.2 | 0.56

    PMID 32284053 · one of two readings recorded this

  • BMI, Wk10 vs Wk0

    no effect, p = 0.32

    Control | 24.2 ± 3.8 | 24.1 ± 3.9 | 0.32

    PMID 32284053 · one of two readings recorded this

  • carbohydrate intake, Wk10 vs Wk0

    no effect, p = 0.18

    48 mg sucralose | 227.9 ± 59.3 | 252.9 ± 86.7 | 0.18

    PMID 32284053 · one of two readings recorded this

  • carbohydrate intake, Wk10 vs Wk0

    no effect, p = 0.42

    96 mg sucralose | 264.7 ± 133.9 | 286.5 ± 132.7 | 0.42

    PMID 32284053 · one of two readings recorded this

  • carbohydrate intake, Wk10 vs Wk0

    no effect, p = 0.12

    Control | 289.4 ± 118.4 | 250.7 ± 123.5 | 0.12

    PMID 32284053 · one of two readings recorded this

  • energy intake, Wk10 vs Wk0

    no effect, p = 0.1

    48 mg sucralose | 1935.9 ± 681.8 | 2170.7 ± 732.3 | 0.10

    PMID 32284053 · one of two readings recorded this

  • energy intake, Wk10 vs Wk0

    no effect, p = 0.65

    96 mg sucralose | 2133.1 ± 965.8 | 2235.7 ± 917.5 | 0.65

    PMID 32284053 · one of two readings recorded this

  • energy intake, Wk10 vs Wk0

    no effect, p = 0.09

    Control | 22 64.8 ± 1247.2 | 1941.6 ± 710.7 | 0.09

    PMID 32284053 · one of two readings recorded this

  • glucose AUC, any sucralose group, Wk10 vs Wk0

    increases, p = 0.01

    for glucose, Wk0 = 18,141 ± 3877 vs Wk10 = 18,885 ± 3332, p = 0.01

    PMID 32284053 · one of two readings recorded this

  • glucose AUC, Bonferroni difference 48 mg vs 96 mg

    no effect, p = 0.29

    96 mg | 1027.96 | 617.01 | 0.29 | −462.79 | 2518.70

    PMID 32284053 · one of two readings recorded this

  • glucose AUC, Bonferroni difference 48 mg vs control

    increases, p = 0.03

    Glucose, AUC | Control | 48 mg | -1537.81 | 603.48 | 0.03a | -2995.85 | −79.77

    PMID 32284053 · one of two readings recorded this

  • glucose AUC, Bonferroni difference 96 mg vs control

    no effect, p = 1

    96 mg | − 509.85 | 598.28 | 1.00 | − 1955.34 | 935.64

    PMID 32284053 · one of two readings recorded this

  • glucose AUC, type-by-time interaction

    no effect, p = 1

    No interaction between type of intervention (control, 48 mg or 96 mg sucralose) and consumption time (Wk0 and Wk10) was found in glucose AUC (F(2,184) = 0.00, p = 1.00)

    PMID 32284053 · one of two readings recorded this

  • glucose AUC, type of intervention main effect

    modulates, p = 0.038

    type of intervention showed a significant effect (F(2,184) = 3.327, p = 0.038, η2 = 0.035, 1-β = 0.624)

    PMID 32284053 · one of two readings recorded this

  • glucose AUC, Wk10 vs Wk0

    no effect, p = 0.05

    48 mg sucralose | 18,267 ± 2858 | 19,408 ± 2904 | 0.05

    PMID 32284053 · one of two readings recorded this

  • glucose AUC, Wk10 vs Wk0

    no effect, p = 0.66

    96 mg sucralose | 18,019 ± 4705 | 18,380 ± 3677 | 0.66

    PMID 32284053 · one of two readings recorded this

  • glucose AUC, Wk10 vs Wk0

    no effect, p = 0.91

    Control | 17,820 ± 2872 | 17,870 ± 3557 | 0.91

    PMID 32284053 · one of two readings recorded this

  • HbA1c, Wk10 vs Wk0

    no effect, p = 0.51

    48 mg sucralose | 5.23 ± 0.21 | 5.26 ± 0.26 | 0.51

    PMID 32284053 · one of two readings recorded this

  • HbA1c, Wk10 vs Wk0

    increases, p = 0.03

    96 mg sucralose | 5.15 ± 0.3 | 5.25 ± 0.26 | 0.03

    PMID 32284053 · one of two readings recorded this

  • HbA1c, Wk10 vs Wk0

    no effect, p = 0.55

    Control | 5.22 ± 0.23 | 5.24 ± 0.24 | 0.55

    PMID 32284053 · one of two readings recorded this

  • insulin AUC, any sucralose group, Wk10 vs Wk0

    increases, p = 0.006

    for insulin, Wk0 = 8093 ± 4687 vs Wk10 = 9871 ± 6253, p = 0.006

    PMID 32284053 · one of two readings recorded this

  • insulin AUC at Wk0, 96 mg versus 48 mg

    no effect, p = 0.06

    AUC Wk0 96 mg = 6962 ± 4899 vs AUC Wk0 48 mg = 9262 ± 4225; p = 0.06

    PMID 32284053 · one of two readings recorded this

  • insulin AUC at Wk10, 48 mg versus control

    no effect, p = 0.07

    AUC Wk10 48 mg = 11,398 ± 6641 vs AUC Wk10 control = 9397 ± 5126; p = 0.07

    PMID 32284053 · one of two readings recorded this

  • insulin AUC at Wk10, 96 mg versus 48 mg

    no effect, p = 0.06

    AUC Wk10 96 mg = 8394 ± 5567 vs AUC Wk10 48 mg = 11,398 ± 6641 p = 0.06

    PMID 32284053 · one of two readings recorded this

  • insulin AUC, Bonferroni difference 48 mg vs 96 mg

    increases, p = 0.02

    96 mg | 2652.20a | 975.45 | 0.02 | 295.45 | 5008.96

    PMID 32284053 · one of two readings recorded this

  • insulin AUC, Bonferroni difference 48 mg vs control

    no effect, p = 0.75

    Insulin, AUC | Control | 48 mg | − 1104.65 | 954.05 | 0.75 | − 3409.70 | 1200.40

    PMID 32284053 · one of two readings recorded this

  • insulin AUC, Bonferroni difference 96 mg vs control

    no effect, p = 0.31

    96 mg | 1547.55 | 945.84 | 0.31 | − 737.66 | 3832.77

    PMID 32284053 · one of two readings recorded this

  • insulin AUC, consumption time main effect (Wk0 vs Wk10)

    no effect, p = 0.1

    it showed a tendency to increase (F(1,184) = 2.77, p = 0.10)

    PMID 32284053 · one of two readings recorded this

  • insulin AUC, type-by-time interaction

    no effect, p = 0.63

    no interaction between type of intervention and consumption time was observed (F(2,184) = 0.45, p = 0.63)

    PMID 32284053 · one of two readings recorded this

  • insulin AUC, type of intervention main effect

    modulates, p = 0.03

    type of intervention had a significant effect on the AUC of insulin (F(2,184) = 3.74, p = 0.03, η2 = 0.039, 1-β = 0.679)

    PMID 32284053 · one of two readings recorded this

  • insulin AUC, Wk10 vs Wk0

    increases, p = 0.02

    48 mg sucralose | 9262 ± 4225 | 11,398 ± 6641 | 0.02

    PMID 32284053 · one of two readings recorded this

  • insulin AUC, Wk10 vs Wk0

    no effect, p = 0.12

    96 mg sucralose | 6962 ± 4899 | 8394 ± 5567 | 0.12

    PMID 32284053 · one of two readings recorded this

  • insulin AUC, Wk10 vs Wk0

    no effect, p = 0.65

    Control | 9054 ± 5571 | 9397 ± 5126 | 0.65

    PMID 32284053 · one of two readings recorded this

  • lipid intake, Wk10 vs Wk0

    no effect, p = 0.1

    48 mg sucralose | 67.6 ± 43.4 | 81.6 ± 40.4 | 0.10

    PMID 32284053 · one of two readings recorded this

  • lipid intake, Wk10 vs Wk0

    no effect, p = 0.63

    96 mg sucralose | 69.2 ± 43.4 | 74.2 ± 40.9 | 0.63

    PMID 32284053 · one of two readings recorded this

  • lipid intake, Wk10 vs Wk0

    no effect, p = 0.29

    Control | 71.6 ± 59.9 | 62.1 ± 26.6 | 0.29

    PMID 32284053 · one of two readings recorded this

  • Matsuda insulin sensitivity index, Wk10 vs Wk0

    decreases, p = 0.01

    48 mg sucralose | 6.04 ± 3.19 | 4.86 ± 2.13 | 0.01

    PMID 32284053 · one of two readings recorded this

  • Matsuda insulin sensitivity index, Wk10 vs Wk0

    no effect, p = 0.3

    96 mg sucralose | 7.93 ± 4.63 | 7.09 ± 4.72 | 0.30

    PMID 32284053 · one of two readings recorded this

  • Matsuda insulin sensitivity index, Wk10 vs Wk0

    no effect, p = 0.09

    Control | 6.8 ± 3.35 | 6.14 ± 3.41 | 0.09

    PMID 32284053 · one of two readings recorded this

  • maximum glucose concentration in OGTT, Wk10 vs Wk0

    no effect, p = 0.09

    48 mg sucralose | 133.06 ± 20.79 | 141.17 ± 18.59 | 0.09

    PMID 32284053 · one of two readings recorded this

  • maximum glucose concentration in OGTT, Wk10 vs Wk0

    no effect, p = 0.46

    96 mg sucralose | 133.45 ± 29.72 | 137.61 ± 25.33 | 0.46

    PMID 32284053 · one of two readings recorded this

  • maximum glucose concentration in OGTT, Wk10 vs Wk0

    no effect, p = 0.41

    Control | 131.94 ± 21.19 | 135.12 ± 23.53 | 0.41

    PMID 32284053 · one of two readings recorded this

  • maximum insulin concentration in OGTT, Wk10 vs Wk0

    increases, p = 0.01

    48 mg sucralose | 106.10 ± 58 | 130.9 ± 60.51 | 0.01

    PMID 32284053 · one of two readings recorded this

  • maximum insulin concentration in OGTT, Wk10 vs Wk0

    no effect, p = 0.48

    96 mg sucralose | 85.42 ± 42.67 | 90.42 ± 50.41 | 0.48

    PMID 32284053 · one of two readings recorded this

  • maximum insulin concentration in OGTT, Wk10 vs Wk0

    no effect, p = 0.34

    Control | 100 ± 56.07 | 108.94 ± 62.15 | 0.34

    PMID 32284053 · one of two readings recorded this

  • protein intake, Wk10 vs Wk0

    no effect, p = 0.86

    48 mg sucralose | 94.4 ± 60.6 | 97.47 ± 44.4 | 0.86

    PMID 32284053 · one of two readings recorded this

  • protein intake, Wk10 vs Wk0

    no effect, p = 0.32

    96 mg sucralose | 100.8 ± 44.4 | 94.9 ± 82.9 | 0.32

    PMID 32284053 · one of two readings recorded this

  • protein intake, Wk10 vs Wk0

    no effect, p = 0.09

    Control | 103.9 ± 74.8 | 84.7 ± 32.9 | 0.09

    PMID 32284053 · one of two readings recorded this

  • serum insulin during OGTT at 0 min, Wk10 vs Wk0

    increases, p = 0.01

    at 0 min (7.5 ± 3.4 μIU/mL vs 8.8 ± 4.1 μIU/mL; p = 0.01)

    PMID 32284053 · one of two readings recorded this

  • serum insulin during OGTT at 105 min, Wk10 vs Wk0

    increases, p = 0.04

    at 105 min (47.7 ± 24.4 μIU/mL vs. 64.3 ± 48.2 μIU/mL; p = 0.04)

    PMID 32284053 · one of two readings recorded this

  • serum insulin during OGTT at 120 min, Wk10 vs Wk0

    increases, p = 0.01

    at 120 min (44.8 ± 22.1 μIU/mL vs. 63.1 ± 47.8 μIU/mL; p = 0.01)

    PMID 32284053 · one of two readings recorded this

  • serum insulin during OGTT at 30 min, Wk10 vs Wk0

    increases, p = 0.05

    at 30 min (91.3 ± 56.2 μIU/mL vs. 110.1 ± 49.4 μIU/mL; p = 0.05)

    PMID 32284053 · one of two readings recorded this

  • time to maximum glucose in OGTT, Wk10 vs Wk0

    no effect, p = 0.11

    48 mg sucralose | 34 ± 18.45 | 40.5 ± 23.35 | 0.11

    PMID 32284053 · one of two readings recorded this

  • time to maximum glucose in OGTT, Wk10 vs Wk0

    no effect, p = 0.58

    96 mg sucralose | 36.77 ± 20.06 | 34.84 ± 19.51 | 0.58

    PMID 32284053 · one of two readings recorded this

  • time to maximum glucose in OGTT, Wk10 vs Wk0

    no effect, p = 1

    Control | 36.18 ± 9.85 | 36.18 ± 20.27 | 1.00

    PMID 32284053 · one of two readings recorded this

  • time to maximum insulin in OGTT, Wk10 vs Wk0

    no effect, p = 0.58

    48 mg sucralose | 40.5 ± 14.82 | 38.5 ± 20.35 | 0.58

    PMID 32284053 · one of two readings recorded this

  • time to maximum insulin in OGTT, Wk10 vs Wk0

    no effect, p = 0.23

    96 mg sucralose | 40.65 ± 17.4 | 45.48 ± 17.53 | 0.23

    PMID 32284053 · one of two readings recorded this

  • time to maximum insulin in OGTT, Wk10 vs Wk0

    no effect, p = 0.5

    Control | 45 ± 19.19 | 48.09 ± 23.87 | 0.50

    PMID 32284053 · one of two readings recorded this

  • fasting plasma GLP-1, ghrelin, PYY and leptin

    no effect

    Sucralose intake is not associated with changes in fasting concentrations of glucagon-like peptide 1, ghrelin, peptide tyrosine tyrosine, or leptin

    PMID 32711853 · one of two readings recorded this

  • HOMA-IR, repeated measures ANOVA, one week after dosing ended

    increases, incremental change in HOMA-IR in the intervention group, p = 0.04

    Not recorded as a finding: the abstract reports a change in the intervention group only, with no between-arm statement, and the sentence does not name sucralose

    One week postintervention, an incremental change (P=0.04) in the homeostasis model assessment of insulin resistance was found in the intervention group.

    PMID 32711853 · one of two readings recorded this

  • HOMA-IR, repeated-measures ANOVA, secondary outcome

    increases, incremental change in HOMA-IR one week postintervention in the intervention group, p = 0.04

    Not recorded as a finding: result is a within-group change at one week post-dosing only, with no between-arm sentence, and the abstract states it of unknown clinical significance

    One week postintervention, an incremental change (P=0.04) in the homeostasis model assessment of insulin resistance was found in the intervention group.

    PMID 32711853 · one of two readings recorded this

  • homeostasis model assessment of insulin resistance

    increases, p = 0.04

    One week postintervention, an incremental change (P=0.04) in the homeostasis model assessment of insulin resistance was found in the intervention group

    PMID 32711853 · one of two readings recorded this

  • glucose, insulin and GLP-1 areas under the curve after MMTT

    increases

    Glucose, insulin and GLP-1 areas under the curve increased after the MMTT, along with a significant decrease in insulin sensitivity after sucralose consumption

    PMID 40907790 · one of two readings recorded this

  • gut microbiota alpha-diversity

    decreases

    A reduction in α-diversity of the gut microbiota was observed

    PMID 40907790 · one of two readings recorded this

  • insulin sensitivity by Matsuda index after a mixed meal tolerance test, 30 % of sucralose acceptable daily intake for 30 days versus placebo; also glucose, insulin and GLP-1 AUC, gut microbiota alpha-diversity, fecal Curli protein

    decreases, 20.3 % decrease in insulin sensitivity

    Not recorded as a finding: this platform holds no node for the endpoint

    The consumption of sucralose in healthy lean individuals for 30 days caused a 20.3 % significant decrease in insulin sensitivity.

    PMID 40907790 · one of two readings recorded this

  • insulin sensitivity by Matsuda index during a mixed meal tolerance test, after 30 days of sucralose versus placebo

    decreases, 20.3 % significant decrease in insulin sensitivity

    Not recorded as a finding: this platform holds no node for the endpoint

    The consumption of sucralose in healthy lean individuals for 30 days caused a 20.3 % significant decrease in insulin sensitivity.

    PMID 40907790 · one of two readings recorded this

  • insulin sensitivity

    decreases

    The consumption of sucralose in healthy lean individuals for 30 days caused a 20.3 % significant decrease in insulin sensitivity

    PMID 40907790 · one of two readings recorded this

  • proinflammatory markers, BCAA, acetate and fecal Curli protein

    increases

    proinflammatory markers, BCAA, acetate, and fecal Curli protein increased, whereas serum glutamic acid and fecal butyrate, decreased after sucralose consumption

    PMID 40907790 · one of two readings recorded this

  • serum glutamic acid and fecal butyrate

    decreases

    proinflammatory markers, BCAA, acetate, and fecal Curli protein increased, whereas serum glutamic acid and fecal butyrate, decreased after sucralose consumption

    PMID 40907790 · one of two readings recorded this

  • faecal/serum butyrate concentration

    no effect, numerical decrease, pooled effect not statistically significant, substantial heterogeneity

    Butyrate showed a numerical decrease, although the pooled effect was not statistically significant and substantial heterogeneity was observed.

    PMID 42794802 · one of two readings recorded this

  • pooled faecal/serum butyrate, short-chain fatty acid production

    no effect, numerical decrease, pooled effect not statistically significant, substantial heterogeneity

    Not recorded as a finding: no outcome node for short-chain fatty acid production

    Butyrate showed a numerical decrease, although the pooled effect was not statistically significant and substantial heterogeneity was observed.

    PMID 42794802 · one of two readings recorded this

  • pooled short-chain fatty acid, butyrate

    Not recorded as a finding: no outcome node exists for short-chain fatty acids/butyrate; also no quantitative estimate stated for this endpoint in the abstract

    Butyrate showed a numerical decrease, although the pooled effect was not statistically significant and substantial heterogeneity was observed.

    PMID 42794802 · one of two readings recorded this